Literature DB >> 22014484

Cross-sectional review of effects of laparoscopic sleeve gastrectomy at 1, 3, and 5 years.

Gladys W Strain1, Taha Saif, Michel Gagner, Micheal Rossidis, Gregory Dakin, Alfons Pomp.   

Abstract

BACKGROUND: Laparoscopic sleeve gastrectomy evolved as a primary bariatric procedure without data on longer term outcomes. Our objective was to measure the weight changes and quality of life after laparoscopic sleeve gastrectomy at a university hospital.
METHODS: The patients scheduled follow-up visits for clinical measurements, blood sampling, and form completion, including the Medical Outcomes Study 36-item short-form questionnaire, the Impact of Weight on the Quality of Life-Lite questionnaire, and Beck depression inventory. Comparisons were performed among patients with a follow-up of 1, 3, and 5 years after laparoscopic sleeve gastrectomy.
RESULTS: A total of 77 patients (35 at 1, 19 at 3, and 23 at 5 yr) were similar in gender (70.1% women), percentage of body fat, and body mass index by analysis of variance (P = .12; 1 versus 3 yr, P = .04). The 5-year group was older (P = .07). The 3 groups were different in the percentage of excess body mass index loss (P = .04). Differences in the Beck depression inventory were not significant by analysis of variance but were for 1 year versus 5 years (P = .04). For the Impact of Weight on the Quality of Life-Lite total scores, the difference was significant (P = .06; 1 versus 5 yr, P = .027; and public distress subscore at 1 and 5 yr, P = .04). The differences in the other domains were not significant. For the Medical Outcomes Study 36-item short-form, differences in the physical differences domain was significant (P = .001). The differences in physical function, social function, general health, vitality, body pain, and role physical were significant. The differences in mental health and role emotional were not. The differences in the Beck depression inventory scores were not significant using analysis of variance but were between the 1-year and 5-year scores (P = .04).
CONCLUSION: Patients undergoing laparoscopic sleeve gastrectomy had a similar body mass index at 1, 3, and 5 years. However, the percentage of excess body mass index loss was different. No differences were found in the percentage of body fat. The health-related quality of life scores resembled community norms, although the physical health differences in the 3 groups were significant, The Beck depression inventory scores were elevated at 5 years compared with at 1 year.
Copyright © 2011 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22014484     DOI: 10.1016/j.soard.2011.08.021

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  16 in total

1.  Lifestyle modification parallels to sleeve success.

Authors:  Dean Keren; Ibrahim Matter; Alexandra Lavy
Journal:  Obes Surg       Date:  2014-05       Impact factor: 4.129

2.  Medium-Term Results of Laparoscopic Sleeve Gastrectomy: a Matched Comparison with Gastric Bypass.

Authors:  Wei-Jei Lee; Eng-Hong Pok; Abdullah Almulaifi; Ju Juin Tsou; Kong-Han Ser; Yi-Chih Lee
Journal:  Obes Surg       Date:  2015-08       Impact factor: 4.129

Review 3.  The impact of obesity surgery on musculoskeletal disease.

Authors:  Ussamah El-Khani; Ahmed Ahmed; Sherif Hakky; Jean Nehme; Jonathan Cousins; Harvinder Chahal; Sanjay Purkayastha
Journal:  Obes Surg       Date:  2014-12       Impact factor: 4.129

4.  Five-year results of laparoscopic sleeve gastrectomy for the treatment of severe obesity.

Authors:  David Nocca; Marcelo Loureiro; El Mehdi Skalli; Marius Nedelcu; Audrey Jaussent; Melanie Deloze; Patrick Lefebvre; Jean Michel Fabre
Journal:  Surg Endosc       Date:  2016-12-23       Impact factor: 4.584

5.  Lipid profile changes in the severely obese after laparoscopic sleeve gastrectomy (LSG), 1, 3, and 5 years after surgery.

Authors:  Gladys W Strain; Taha Saif; Faith Ebel; Gregory F Dakin; Michel Gagner; Ricardo Costa; Ya-Lin Chiu; Alfons Pomp
Journal:  Obes Surg       Date:  2015-02       Impact factor: 4.129

6.  Long-Term Results of Laparoscopic Sleeve Gastrectomy for Morbid Obesity: 5 to 8-Year Results.

Authors:  Ralph P M Gadiot; L Ulas Biter; Stefanie van Mil; Hans F Zengerink; J Apers; Guido H H Mannaerts
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

7.  Five-Year Outcomes After Vertical Sleeve Gastrectomy for Severe Obesity: A Prospective Cohort Study.

Authors:  Tone Nygaard Flølo; John R Andersen; Ronette L Kolotkin; Anny Aasprang; Gerd K Natvig; Karl O Hufthammer; Villy Våge
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

8.  6-Month Gastrointestinal Quality of Life (QoL) Results after Endoscopic Sleeve Gastroplasty and Laparoscopic Sleeve Gastrectomy: A Propensity Score Analysis.

Authors:  Claudio Fiorillo; Giuseppe Quero; Michel Vix; Ludovica Guerriero; Margherita Pizzicannella; Alfonso Lapergola; Antonio D'Urso; Lee Swanstrom; Didier Mutter; Bernard Dallemagne; Silvana Perretta
Journal:  Obes Surg       Date:  2020-05       Impact factor: 4.129

9.  A Multi-institutional Study on the Mid-Term Outcomes of Single Anastomosis Duodeno-Ileal Bypass as a Surgical Revision Option After Sleeve Gastrectomy.

Authors:  Hinali Zaveri; Amit Surve; Daniel Cottam; Peter C Ng; Paul Enochs; Helmuth Billy; Walter Medlin; Christina Richards; LeGrand Belnap; Lindsey S Sharp; Dustin M Bermudez; Ryan Fairley; Tricia A Burns; Krista Herrell; Jaime Bull; Sophia E Menozzi; John Ambrose Student
Journal:  Obes Surg       Date:  2019-10       Impact factor: 4.129

10.  Safety and efficacy of 1020 consecutive laparoscopic sleeve gastrectomies performed as a primary treatment modality for morbid obesity. A single-center experience from the metabolic and bariatric surgical accreditation quality and improvement program.

Authors:  Emanuela Silva Alvarenga; Emanuele Lo Menzo; Samuel Szomstein; Raul J Rosenthal
Journal:  Surg Endosc       Date:  2015-11-05       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.